Vericel Corporation (VCEL) Dividend History

Vericel Corporation (VCEL) is a biotechnology company specializing in the development and commercialization of autologous cell therapy products for the treatment of sports-related injuries, including cartilage and tendon repair. The company focuses on regenerative medicine technologies aimed at improving patient outcomes in musculoskeletal conditions.

64 Sidney St., Cambridge, MA, 02139
Phone: (734) 930-5555

Dividend History

Vericel Corporation currently does not pay dividends

Company News

  • Vericel Corporation reported strong financial results for the second quarter of 2024, with record revenue, MACI revenue growth, and significant margin expansion. The company also provided an update on the progress of its NexoBrid launch and raised its full-year profitability guidance.

    GlobeNewswire Inc.
  • Vericel Corp's Chief Legal Officer, Sean C. Flynn, has sold $782,700 worth of company stock as part of a prearranged trading plan. The transaction comes amid the company's strong financial performance and positive analyst coverage.

    Investing.com
  • Throughout the last three months, 4 analysts have evaluated Vericel (NASDAQ:VCEL), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 2 0 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $54.0, a high estimate of $55.00, and a low estimate of $53.00. This current average has increased by 5.88% from the previous average price target of $51.00. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Vericel by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $55.00 $53.00 Samuel Brodovsky Truist Securities Maintains Buy $54.00 $54.00 Samuel Brodovsky Truist Securities Raises Buy $54.00 $51.00 Swayampakula Ramakanth HC Wainwright & Co. Raises Buy $53.00 $46.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their ...Full story available on Benzinga.com

    Benzinga
  • Vericel Corporation (VCEL) delivered earnings and revenue surprises of 44.44% and 0%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: EYPT
  • VCEL earnings call for the period ending June 30, 2022.

    The Motley Fool
Page data last updated 07/23/2025 21:52:32 UTC